Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: September 26, 2022

Details for Patent: 7,498,343

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 7,498,343 protect, and when does it expire?

Patent 7,498,343 protects SIRTURO and is included in one NDA.

This patent has fifty-seven patent family members in thirty-five countries.

Summary for Patent: 7,498,343
Title:Mycobacterial inhibitors
Abstract: The present invention relates to novel substituted quinoline derivatives according to the general Formula (Ia) or the general Formula (Ib) ##STR00001## the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the N-oxide forms thereof. The claimed compounds are useful for the treatment of mycobacterial diseases, particularly those diseases caused by pathogenic mycobacteria such as Mycobacterium tuberculosis, M. bovis, M. avium and M. marinum. In particular, compounds are claimed in which, independently from each other, R.sup.1 is bromo, p=1, R.sup.2 is alkyloxy, R.sup.3 is optionally substituted naphthyl or phenyl, q=1, R.sup.4 and R.sup.5 each independently are hydrogen, methyl or ethyl, R.sup.6 is hydrogen, r is equal to 0 or 1 and R.sup.7 is hydrogen. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of the claimed compounds or compositions for the manufacture of a medicament for the treatment of mycobacterial diseases and a process for preparing the claimed compounds.
Inventor(s): Van Gestel; Jozef Frans Elisabetha (Beerse, BE), Guillemont; Jerome Emile Georges (Val de Reuil Cedex, FR), Venet; Marc Gaston (Le Mans, FR), Poignet; Herve Jean Joseph (Issy-les-Moulineaux Cedex 9, FR), Decrane; Laurence Francoise Bernadette (Val de Reuil Cedex, FR), Vernier; Daniel F. J. (Val de Reuil Cedex, FR), Odds; Frank Christopher (Drumoak, GB)
Assignee: Janssen Pharmaceutica N.V. (Beerse, BE)
Application Number:11/007,026
Patent Claim Types:
see list of patent claims
Compound; Composition; Use; Process;

Drugs Protected by US Patent 7,498,343

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Janssen Therap SIRTURO bedaquiline fumarate TABLET;ORAL 204384-002 May 27, 2020 RX Yes No See Plans and Pricing See Plans and Pricing Y Y TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS See Plans and Pricing
Janssen Therap SIRTURO bedaquiline fumarate TABLET;ORAL 204384-001 Dec 28, 2012 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,498,343

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 2421 See Plans and Pricing
Argentina 040673 See Plans and Pricing
Austria 463482 See Plans and Pricing
Australia 2003262529 See Plans and Pricing
Brazil 0312927 See Plans and Pricing
Brazil PI0312927 See Plans and Pricing
Canada 2493225 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.